Alkermes has launched the Brilliance Studies, a Phase 3 clinical trial program that will evaluate the safety and effectiveness of alixorexton, its once-daily oral therapy candidate for people with narcolepsy types 1…

Modafinil, sold under the brand name Provigil among others, significantly eases excessive daytime sleepiness in people with narcolepsy, according to a new systematic review and meta-analysis. Across more than a half dozen…

A new data-driven model has identified narcolepsy — a condition characterized by the brain’s inability to regulate sleep-wake cycles — as a key driver of excessive daytime sleepiness (EDS), which is marked by chronic,…